Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
GlobeNewswire
*•* Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American..
*•* Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American..
2023 Revenue Growth of 7% with 9% Organic Growth including 21% Growth in AMS and DRS
Record Full-Year 2023 Net Cash from..
By Kung Chan and Xia Ri
Since the outbreak of the COVID-19 pandemic in 2020, the United States has implemented..